报价延迟最少15分钟:2025/09/17 22:32 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
175.43 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.91/-0.88
|
|
企业价值
24.12B
|
| 资产负债 |
|
每股账面净值
9.08
|
| 现金流量 |
|
现金流量率
0.01
|
| 损益表 |
|
收益
1.70B
|
|
每股收益
6.78
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/17 22:32 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. |
